We are live on ! Find out more
TRV

Third Rock Ventures Portfolio holdings

AUM $1.07B
1-Year Est. Return 170.23%
This Fund
S&P 500
This Quarter Est. Return
+4.8%
1 Year Est. Return
+170.23%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$857M
AUM Growth
+$389M
Cap. Flow
+$366M
Cap. Flow %
42.68%
Top 10 Hldgs %
100%
Holding
6
New
2
Increased
–
Reduced
2
Closed
–

Top Buys

Rank Stock Value
1
SAGE
Sage Therapeutics
SAGE
+$338M
2
LRMR icon
Larimar Therapeutics
LRMR
+$106M

Top Sells

Rank Stock Value
1
BLUE
bluebird bio
BLUE
+$42.8M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$35.6M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SAGE
1
DELISTED
Sage Therapeutics
SAGE
$368M 42.92%
+11,681,008
New +$338M
AGIO icon
2
Agios Pharmaceuticals
AGIO
$2.38B
$188M 21.97%
3,070,090
-825,000
-21% -$35.6M
LRMR icon
3
Larimar Therapeutics
LRMR
$398M
$110M 12.84%
+466,837
New +$106M
FMI
4
DELISTED
Foundation Medicine, Inc.
FMI
$93.4M 10.9%
4,927,234
– –
CARM
5
DELISTED
Carisma Therapeutics
CARM
$53.9M 6.29%
242,080
– –
BLUE
6
DELISTED
bluebird bio
BLUE
$43.6M 5.09%
93,802
-92,788
-50% -$42.8M

Similar funds

AH
Achievement Holdings Chicago, Illinois $1.2B AUM 9.2% 1-Year Est. Return
GHF
Good Harbor Financial Barrington, Illinois $916M AUM 5.96% 1-Year Est. Return
CWA
Constellation Wealth Advisors New York $903M AUM 2.38% 1-Year Est. Return
RI
Relational Investors San Diego, California $840M AUM 0.57% 1-Year Est. Return
TCM
Tamarack Capital Management Carlsbad, California $840M AUM 19.47% 1-Year Est. Return
F
FutureAdvisor San Francisco, California $617M AUM 6.57% 1-Year Est. Return
MCC
Mid Continent Capital Chicago, Illinois $1.54B AUM 0.7% 1-Year Est. Return
OA
OFI Advisors Philadelphia, Pennsylvania $1.55B AUM 1.44% 1-Year Est. Return

Third Rock Ventures's Q3 2014 Portfolio in Review

As of Q3 2014, Third Rock Ventures held 6 positions worth $857M, up 83% from $468M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Third Rock Ventures deployed $366M of net new capital in Q3 2014, opening 2 new positions. Its largest new stake was Sage Therapeutics: 11,681,008 shares worth $368M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was bluebird bio, an estimated $42.8M trimmed.

  • Third Rock Ventures's largest Q3 2014 buy was Sage Therapeutics: 11,681,008 shares worth $368M.
  • Third Rock Ventures's biggest Q3 2014 reduction was bluebird bio, cutting an estimated $42.8M.
  • Third Rock Ventures's ten largest holdings make up 100% of its $857M portfolio in Q3 2014.
  • Third Rock Ventures opened 2 new positions and closed 0 in Q3 2014.
  • Third Rock Ventures's portfolio value rose 83% quarter-over-quarter to $857M.

Based on Third Rock Ventures's 13F filing for Q3 2014, filed 22 Oct 2014.